KFAS
NKTR icon

Keating Financial Advisory Services’s Nektar Therapeutics NKTR Stock Holding History

Keating Financial Advisory Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18
Closed -$1.29K – 2677
2026
Q1 		$1.29K Sell
18
-51
-74% -$2.9K ﹤0.01% 2008
2025
Q4 		$2.92K Buy
+69
New +$3.86K ﹤0.01% 1466

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's NKTR Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 18 shares — an estimated $1.29K sold.

Keating Financial Advisory Services first reported a position in NKTR in Q4 2025 and held it in 2 quarters. The position peaked at $2.92K in Q4 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 18 Nektar Therapeutics shares in Q2 2026, an estimated $1.29K.
  • Keating Financial Advisory Services first reported a position in Nektar Therapeutics in Q4 2025 and held it in 2 quarters.
  • Keating Financial Advisory Services's Nektar Therapeutics position peaked at $2.92K in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.